The association of Enasidenib with 5-azacytidine in first line IDH-mutated AML also shows interesting results with 71% overall response rate (ORR) for the combination, compared to 42% for 5-azacytidine alone (p = 0.0064) [112]. The gene discussed is IDH2; the disease is acute myeloid leukemia.